Jun 21, 2005 by Brian GormanGenentech Hedges Its EdgeThe company's manufacturing capacity may allow it to attract biotech partners for years into the future.
Jun 20, 2005 by Brian GormanGains From GrainsGeneral Mills' attempt to set the standard in whole grains could mean a big payoff.
Jun 17, 2005 by Brian GormanJapan Looks to the SkiesIts recent agreement with France is another sign that the commercial aerospace market could soon have a new player.
Jun 17, 2005 by Brian GormanToo Many Hybrids?A gas-electric car may not bring Nissan explosive growth.
Jun 17, 2005 by Brian GormanYahoo!'s Superfluous ServiceSearch subscription-only sites -- but only if you already subscribe.
Jun 16, 2005 by Brian GormanCan Hershey Get Hip?The company's new Chicago retail complex aims to spruce up its brand.
Jun 16, 2005 by Brian GormanCosi Gets More BreadAs it expands, the restaurant operator may need to boost its marketing budget.
Jun 15, 2005 by Brian GormanPatented Drugs Fair Game in R&DThe Supreme Court's ruling could be bad news for investors in small pharma and biotech.
Jun 14, 2005 by Brian GormanSirius Moves to the CenterSirius' strategies suggest that satellite radio success lies with broad audience appeal.
Jun 13, 2005 by Brian GormanTrinity Almost On TrackEarnings continue to improve, even as the railcar maker's balance sheet has suffered.
Jun 13, 2005 by Brian GormanWalgreen Strikes BackThe traditional drugstore operator is expanding its mail-order business.
Jun 10, 2005 by Brian GormanPAREXEL's New RiskThe company is realigning its business, but even with reduced U.S. operations, it faces increased risk.
Jun 9, 2005 by Brian GormanTanker TangoEurope's aerospace leader and Northrop Grumman team up, pursuing a key defense contract.
Jun 9, 2005 by Brian Gorman7-Eleven's Cool New TreatThe company's latest innovation is another example of its astute strategy.
Jun 7, 2005 by Brian GormanCovance Under FireThe contract research company could suffer at the hands of the animal-rights group PETA.
Jun 6, 2005 by Brian GormanChrysler's RenaissanceDaimlerChrysler's top brand is likely to see continued strength in the U.S. and Europe.
Jun 3, 2005 by Brian GormanMerck's New InnovationPending FDA approval, the company's experimental shingles vaccine will probably be a steady earner.
